La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Collegium Pharmaceutical Dividende

Dividende contrôle des critères 0/6

Collegium Pharmaceutical does not have a record of paying a dividend.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	2.2%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	US$3.10
Prévisions de rendement du dividende à 3 ans	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Collegium Pharmaceutical: Diversifying And Growing

Aug 09

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Jul 24

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Insufficient data to determine if COLL's dividends per share have been stable in the past.

Dividende croissant: Insufficient data to determine if COLL's dividend payments have been increasing.

Rendement des dividendes par rapport au marché

Collegium Pharmaceutical Rendement des dividendes par rapport au marché

Comment le rendement du dividende de COLL se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (COLL)	n/a
25% du marché (US)	1.5%
25% du marché (US)	4.4%
Moyenne du secteur (Pharmaceuticals)	2.2%
Prévisions des analystes dans 3 ans (COLL)	n/a

Dividende notable: Unable to evaluate COLL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividende élevé: Unable to evaluate COLL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Bénéfice distribué aux actionnaires

Couverture des revenus: Insufficient data to calculate COLL's payout ratio to determine if its dividend payments are covered by earnings.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as COLL has not reported any payouts.

Collegium Pharmaceutical Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Second quarter 2024 earnings: EPS misses analyst expectations

Collegium Pharmaceutical: Diversifying And Growing

Collegium Pharmaceutical, Inc. Provides Net Product Revenues Guidance for the Second Quarter Ended June 30, 2024; Reaffirms Financial Guidance for the Full Year 2024

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) agreed to acquire Ironshore Therapeutics Inc. for approximately CAD 550 million.

Collegium Pharmaceutical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Price target increased by 8.6% to US$41.00

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

New minor risk - Insider selling

Executive VP & Chief Commercial Officer recently sold US$1.1m worth of stock

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Announces CEO Transition

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical, Inc. to Report Q1, 2024 Results on May 09, 2024

Collegium Pharmaceutical, Inc., Annual General Meeting, May 16, 2024

Investor sentiment improves as stock rises 15%

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Collegium Pharmaceutical Q4: The Beat Goes On

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS exceeds analyst expectations

Collegium Pharmaceutical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Executive VP & Chief Commercial Officer notifies of intention to sell stock

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Price target increased by 13% to US$37.75

President notifies of intention to sell stock

Executive VP exercised options and sold US$253k worth of stock

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

New minor risk - Shareholder dilution

Collegium Pharmaceutical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Collegium Pharmaceutical, Inc. Announces Extension of Nucynta Regulatory Exclusivity Through July 2026

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023

Collegium Pharmaceutical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 8.3% to US$33.25

Executive VP notifies of intention to sell stock

President notifies of intention to sell stock

Collegium Pharmaceutical, Inc. Reaffirms Product Revenues Guidance for Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & CFO notifies of intention to sell stock

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 12% to US$36.00

Executive VP notifies of intention to sell stock

Collegium Pharmaceutical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Price target increased to US$34.00

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2023

Co-Founder & Chairman notifies of intention to sell stock

Appeals Court Affirms Validity of Collegium's Belbuca(R) Patents

Co-Founder & Chairman exercised options and sold US$1.3m worth of stock

President notifies of intention to sell stock

Insufficient new directors

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2022

Third quarter 2022 earnings released: EPS: US$0.013 (vs US$0.23 in 3Q 2021)

Collegium Pharmaceutical, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Executive VP & CFO notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to US$31.40

Collegium Pharmaceutical, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Consensus forecasts updated

Investor sentiment improved over the past week

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind